Literature DB >> 19123201

Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer.

Michael C J Quinn1, Abdelali Filali-Mouhim, Diane M Provencher, Anne-Marie Mes-Masson, Patricia N Tonin.   

Abstract

Tumor suppression as a consequence of the transfer of chromosome 3p fragments was previously observed in a novel epithelial ovarian cancer (EOC) OV-90 cell line model harboring loss of 3p. Microarray analysis revealed that tumor suppression was associated with a modified transcriptome. To investigate the relevance of the altered transcriptome, the differentially expressed genes identified by Affymetrix analysis in the 3p transfer studies, were integrated with a comparative microarray analysis of normal ovarian surface epithelial (NOSE) cells and malignant ovarian (TOV) cancers. Data from 219 significantly differentially expressed genes exhibited patterns in the direction predicted by the analysis of 3p transfer study. The 30 genes with the highest statistically significant differences (P < 1 x 10(-8)) in expression were found consistently differentially expressed between NOSE and TOV samples. The investigation of these genes in benign serous ovarian tumors and EOC cell lines also exhibited predictable expression patterns. Within the group of differentially expressed genes were SPARC, DAB2, CP, EVI1, ELF3, and EHD2, known to play a role in ovarian cancer, genes implicated in other cancers, such as GREM1 and GLIPR1, as well as genes not previously reported in a cancer context such as AKAP2 and ATAD4. A number of the differentially expressed genes are implicated in the TGF-beta signaling pathway. These findings suggest that the reprogramming of the transcriptome that occurred as a consequence of the chromosome 3 transfer and tumor suppression affected molecular networks that are characteristic of ovarian carcinogenesis thus validating our novel ovarian cancer cell line model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19123201     DOI: 10.1002/mc.20511

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  13 in total

1.  VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer.

Authors:  Karen Gambaro; Michael C J Quinn; Paulina M Wojnarowicz; Suzanna L Arcand; Manon de Ladurantaye; Véronique Barrès; Jean-Sébastien Ripeau; Ann M Killary; Elaine C Davis; Josée Lavoie; Diane M Provencher; Anne-Marie Mes-Masson; Mario Chevrette; Patricia N Tonin
Journal:  Mol Oncol       Date:  2013-01-16       Impact factor: 6.603

Review 2.  Glioma pathogenesis-related protein 1 performs dual functions in tumor cells.

Authors:  Junjie Wang; Zeyu Li; Fenfen Yin; Rui Zhang; Ying Zhang; Zhengxin Wang; Xiumei Sheng
Journal:  Cancer Gene Ther       Date:  2021-03-19       Impact factor: 5.987

3.  The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.

Authors:  Paulina M Wojnarowicz; Kathleen Klein Oros; Michael C J Quinn; Suzanna L Arcand; Karen Gambaro; Jason Madore; Ashley H Birch; Manon de Ladurantaye; Kurosh Rahimi; Diane M Provencher; Anne-Marie Mes-Masson; Celia M T Greenwood; Patricia N Tonin
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

4.  Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer.

Authors:  Isabelle J Létourneau; Michael C J Quinn; Lu-Lin Wang; Lise Portelance; Katia Y Caceres; Louis Cyr; Nathalie Delvoye; Liliane Meunier; Manon de Ladurantaye; Zhen Shen; Suzanna L Arcand; Patricia N Tonin; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  BMC Cancer       Date:  2012-08-29       Impact factor: 4.430

5.  Genome-wide profiling of pluripotent cells reveals a unique molecular signature of human embryonic germ cells.

Authors:  Nikta Pashai; Haiping Hao; Angelo All; Siddharth Gupta; Raghothama Chaerkady; Alejandro De Los Angeles; John D Gearhart; Candace L Kerr
Journal:  PLoS One       Date:  2012-06-21       Impact factor: 3.240

6.  Variable Expression of GLIPR1 Correlates with Invasive Potential in Melanoma Cells.

Authors:  Anshul Awasthi; Adele G Woolley; Fabienne J Lecomte; Noelyn Hung; Bruce C Baguley; Sigurd M Wilbanks; Aaron R Jeffs; Joel D A Tyndall
Journal:  Front Oncol       Date:  2013-08-30       Impact factor: 6.244

7.  A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population.

Authors:  Curtis W McCloskey; Reuben L Goldberg; Lauren E Carter; Lisa F Gamwell; Ensaf M Al-Hujaily; Olga Collins; Elizabeth A Macdonald; Kenneth Garson; Manijeh Daneshmand; Euridice Carmona; Barbara C Vanderhyden
Journal:  Front Oncol       Date:  2014-03-18       Impact factor: 6.244

8.  The chemiluminescence based Ziplex automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip expression profiles.

Authors:  Michael C J Quinn; Daniel J Wilson; Fiona Young; Adam A Dempsey; Suzanna L Arcand; Ashley H Birch; Paulina M Wojnarowicz; Diane Provencher; Anne-Marie Mes-Masson; David Englert; Patricia N Tonin
Journal:  J Transl Med       Date:  2009-07-06       Impact factor: 5.531

9.  Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity.

Authors:  P Wojnarowicz; K Gambaro; M de Ladurantaye; M C J Quinn; D Provencher; A-M Mes-Masson; P N Tonin
Journal:  Oncogenesis       Date:  2012-09-10       Impact factor: 7.485

10.  BMP-2 signaling in ovarian cancer and its association with poor prognosis.

Authors:  Cécile Le Page; Marie-Line Puiffe; Liliane Meunier; Magdalena Zietarska; Manon de Ladurantaye; Patricia N Tonin; Diane Provencher; Anne-Marie Mes-Masson
Journal:  J Ovarian Res       Date:  2009-04-14       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.